ICU Medical Inc. (ICUI) stock plummeted 5.04% in Friday's intraday trading session, significantly underperforming the broader market. The medical device company's share price decline came after it provided a disappointing earnings outlook for 2025 in its Q4 2024 earnings call.
According to the earnings transcript, ICU Medical expects its adjusted earnings per share (EPS) for 2025 to range between $6.55 and $7.25, falling short of analyst expectations. The company cited several factors contributing to the weaker-than-anticipated earnings guidance, including higher interest expenses, increased labor costs at its Mexican plants, and the impact of the new global minimum tax on its Costa Rica operations.
Furthermore, ICU Medical announced that it is deconsolidating its IV Solutions business into a joint venture with Otsuka Pharmaceutical Factory, set to close in Q2 2025. While the move is expected to improve the company's gross margins in the long run, the deconsolidation will result in a reduction of $350 million in adjusted revenue and $25 million in adjusted EBITDA for the year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。